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Abstract: Candida auris is a multidrug-resistant fungal pathogen that can cause disseminated bloodstream infections with up to 60% mortality in susceptible populations. Of the three major classes
of antifungal drugs, most C. auris isolates show high resistance to azoles and polyenes, with some
clinical isolates showing resistance to all three drug classes. We reported in this study a novel approach to treating C. auris disseminated infections through passive transfer of monoclonal antibodies
(mAbs) targeting cell surface antigens with high homology in medically important Candida species.
Using an established A/J mouse model of disseminated infection that mimics human candidiasis,
we showed that C3.1, a mAb that targets β-1,2-mannotriose (β-Man3 ), significantly extended survival
and reduced fungal burdens in target organs, compared to control mice. We also demonstrated that
two peptide-specific mAbs, 6H1 and 9F2, which target hyphal wall protein 1 (Hwp1) and phosphoglycerate kinase 1 (Pgk1), respectively, also provided significantly enhanced survival and reduction of
fungal burdens. Finally, we showed that passive transfer of a 6H1+9F2 cocktail induced significantly
enhanced protection, compared to treatment with either mAb individually. Our data demonstrate
the utility of β-Man3 - and peptide-specific mAbs as an effective alternative to antifungals against
medically important Candida species including multidrug-resistant C. auris.
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1. Introduction
Candida auris is an emerging fungal pathogen first identified in Tokyo, Japan in 2009 [1].
It has since emerged throughout much of the world, with many countries reporting multiple
clinical cases [2]. Unlike other pathogenic Candida species, C. auris has a propensity to
colonize abiotic surfaces as well as the human skin [3]. This makes the nosocomial spread
of the pathogen especially prevalent and contributes to a higher potential to disseminate
into bloodstream infections compared to other Candida species. Consequently, ICU patients
and nursing home residents are highly vulnerable to nosocomial infections with C. auris,
and migration from the skin to a disseminated bloodstream infection is especially common
in patients with underlying comorbidities, those under immunosuppressed conditions,
or those who have undergone invasive surgical interventions [4,5]. This ease of spread
has contributed to a slew of healthcare-associated outbreaks, with contamination of ICUs
persisting for several weeks [2,6]. Furthermore, with the ongoing COVID-19 pandemic
caused by the novel coronavirus, SARS-CoV-2, the rate of hospitalizations is currently
extremely high. With many ICU units being filled to capacity, this creates the perfect
environment for further C. auris ICU outbreaks [7–9]. Once systemic, C. auris infection is
often fatal, having a case mortality rate of 33–60% [4,10–12], which is much higher than
that of other pathogenic Candida species. Mortality is most often attributed to multiorgan
failure, with the kidney and heart being most susceptible [13–15].
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A defining feature of C. auris, among other Candida species, is its multidrug resistance.
Although antifungal resistance has been reported in other Candida species, most notably
with Candida glabrata, the degree of antifungal resistance observed in C. auris is unprecedented [2]. In a study that looked at antifungal resistance in 99 clinical isolates of C. auris
from the United States, 89% of isolates were resistant to fluconazole, 30% were resistant
to amphotericin B, and 6% were resistant to echinocandin drugs [16]. In another study
of 1385 United States clinical isolates of C. glabrata, 9.6% of isolates were resistant to fluconazole and 6% were resistant to echinocandin drugs [17]. Similarly, C. auris clinical
isolates from across the globe have consistently shown high resistance to antifungals within
the azole and polyene drug classes [4,18]. Being so, the typical course of treatment for
C. auris bloodstream infections is the daily administration of echinocandin drugs, such as
micafungin, caspofungin, or anidulafungin. A major limitation of antifungals, however,
is their associated drug toxicities. Immunocompromised patients, who are most susceptible
to disseminated infection, are in a fragile state and often unable to tolerate additional organ
toxicity caused by commonly prescribed antifungal drugs, therefore rending these drugs
ineffective [19]. Furthermore, there have been several reports of C. auris isolates that are
pan-resistant to all three major antifungal drug classes, which greatly limits treatment
options [4]. Due to its high degree of antifungal resistance, the potential to spread throughout the hospital environment, and its associated high mortality rate, C. auris is the first
fungal pathogen to be labeled a serious global public health threat, and new treatments are
urgently needed [20].
To overcome the problems of C. auris antifungal resistance and drug toxicity, we sought
to investigate if prophylactic treatment using Candida-specific monoclonal antibodies
(mAbs) could induce protection against C. auris bloodstream infections in A/J mice, as an
alternative to conventional antifungal drug treatment. Protective mAb therapy is an
emerging, yet highly promising strategy for the treatment of microbial diseases [21,22].
Antibodies are known to confer protection to various pathogens via several mechanisms,
including neutralization, opsonization, and complement activation [23]. As of today,
the United States Food and Drug Administration (FDA) has approved five different synthetic mAb for the treatment of various viral and bacterial diseases, including human
immunodeficiency virus (HIV) and Clostridioides difficile infections [24]. Additionally,
two new synthetic mAb-based treatments, Eli Lilly’s Bamlanivimab and Regeneron’s
REGN-COV2 cocktail, are currently in clinical trials and have shown promising efficacy
against COVID-19 [25], and the FDA has approved both drugs for emergency use authorization (EUA) [26,27]. Presently, there are no mAb-derived drugs for the treatment of fungal
diseases, even within clinical trials. Particularly with pathogens such as C. auris, which have
developed high levels of drug resistance and cause high mortality in immunocompromised
patients, mAb therapy is an attractive treatment option.
Since the cell wall is the first point of contact between Candida and the host’s immune
system, we developed “universal mAbs” that target various Candida cell wall epitopes that
share high homology among various Candida species. A major benefit of universal mAbs is
that they could potentially be applied for the treatment of candidemia caused by multiple
pathogenic species of Candida, such as Candida albicans, Candida glabrata, Candida tropicalis,
Candida krusei, and C. auris. This is especially important because infected individuals often
do not receive a timely diagnosis due to unspecific symptoms of invasive candidiasis.
Overall, we hypothesized that prophylactic treatment with universal mAbs would
induce extended survival and enhanced fungal clearance within an A/J mouse model of
C. auris disseminated infection. A/J mice are deficient in complement protein C5 and its
cleaved product C5a, a pro-inflammatory chemoattractant important for anti-Candida protection [28–30]. This renders A/J mice highly susceptible to C. auris disseminated infection
without the need for immunosuppressive drugs [31]. Using this model, we identified three
mAbs that provided significant protection, as evidenced by extended survival and lower
fungal burdens in the kidney, brain, and heart, compared to control mice. In addition,
our results showed that two of our mAbs could be administered as a cocktail to further
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enhance their effectiveness. Overall, our results demonstrate the efficacy of passive transfer
with universal mAbs as a novel treatment against multidrug-resistant C. auris.
2. Results
2.1. In Vitro and In Vivo Efficacy of Antifungals against Multidrug-Resistant C. auris
C. auris isolates can be grouped into five clades (I-V) originating from different geographic regions [4]. Within each clade, isolates may have differences in morphology,
levels of virulence, growth rates, and antifungal-resistance profiles [4,32]. Being so, in preparation for our animal studies, we first investigated the antifungal susceptibility of two
clinical isolates of C. auris belonging to distinct clades: AR-0386 (CAU-06) of Clade IV and
AR-0389 (CAU-09) of Clade I. AR-0386 is a highly aggregative South American isolate that
has been shown to be less virulent than C. albicans in mouse models [33], while AR-0389 is
a nonaggregative South Asian isolate that is highly virulent in mouse models [31,34]. It has
been reported that nonaggregating C. auris isolates such as AR-0389 are among the most
virulent clinical isolates, with virulence comparable to that of C. albicans in the invertebrate
Galleria mellonella model [35].
We first performed an in vitro minimum inhibitory concentration (MIC) assay using
two commonly administered antifungal drugs, micafungin, and itraconazole. These two
antifungals belong to the echinocandin and azole drug classes, respectively, and isolates
AR-0386 and AR-0389 have been reported to be susceptible to both drugs in vitro [34,36].
As a comparison, we also tested the MICs for C. albicans reference strain SC5314. After 48-h
of drug exposure, the micafungin MIC50 was determined to be 0.063 µg/mL for AR-0386,
0.125 µg/mL for AR-0389, and 0.031 µg/mL for C. albicans (Table 1). For itraconazole,
the 48 h MIC50 was 2.0 µg/mL for AR-0386, 0.25 µg/mL for AR-0389, and 0.031 µg/mL for
C. albicans. These results showed that AR-0386 and AR-0389 were susceptible to micafungin
and itraconazole in vitro, although both isolates were much more resistant to itraconazole
than was C. albicans.
Table 1. Micafungin and itraconazole MIC50 for C. auris isolates AR-0386 and AR-0389 and C. albicans
isolate SC5314 at 24 and 48 h.
Drug
Micafungin
Itraconazole

AR-0386 MIC50 (µg/mL)

AR-0389 MIC50 (µg/mL)

SC5314 MIC50 (µg/mL)

24 h

48 h

24 h

48 h

24 h

48 h

0.031
2.0

0.063
2.0

0.063
2.0

0.125
0.25

0.031
0.031

0.031
0.031

A limitation of in vitro assays is that they reflect the limited environment within the
test tube, which is considerably different from the environmental conditions encountered
in vivo. Being that MIC data cannot always reliably predict in vivo drug susceptibility [37],
we next tested the micafungin and itraconazole susceptibility of C. auris using a complement
C5-deficient A/J mouse model of disseminated infection [33]. To begin, we established
an appropriate sublethal challenge dose that would result in 80–100% survival within
10 days post challenge using the highly virulent AR-0389 strain (Figure 1A). Our results
showed that doses below 8 × 107 CFUs resulted in 100% survival by day 10. Accordingly,
we decided to use a dose of 4 × 107 CFUs for our in vivo antifungal susceptibility study.
After the challenge, mice were treated daily with a minimum protective dose of micafungin (0.25 mg/kg/day) or itraconazole (1.67 mg/kg/day), which were determined via an
antifungal pilot study (data not shown). Upon termination on Day 6, micafungin-treated
mice showed no reduction in fungal burdens in the kidney, brain, or heart compared to
control mice (Figure 1B). Similarly, itraconazole provided no significant reduction in organ
burdens using the minimum dose.
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Figure 1. In vivo efficacy of antifungals against multidrug-resistant C. auris: (A) the 10-day survival
curve of 7-week-old female A/J mice challenged with C. auris AR-0389 doses ranging from 1 × 107
to 1 × 108 CFUs; (B) quantification of kidney, brain, and heart fungal burdens from 7-week-old
female A/J treated daily for 5 days with a minimum protective dose of micafungin or itraconazole.
Mice were challenged with a sub-lethal dose of 4 × 107 CFUs of C. auris isolate AR-0389. Starting
24 h later, mice received daily administration of 200 µL of DPBS, micafungin (0.25 mg/kg body
weight), or itraconazole (1.67 mg/kg body weight). Mice were sacrificed on day 6 post challenge;
(C) quantification of kidney and brain fungal burdens from 16- to 17-week-old male and female
neutropenic C57BL/6 mice treated daily for 14 days with a minimum protective dose of micafungin
or itraconazole. To induce neutropenia, mice were administered cyclophosphamide (200 mg/kg body
weight) on day 3 and every 7 days after (150-mg/kg body weight). On day 0, mice were challenged
with a sublethal dose of 4 × 107 CFUs of C. auris isolate AR-0389. Starting 24 h later, mice received
daily administration of 200 µL of DPBS, micafungin (0.25 mg/kg body weight), or itraconazole
(5.0 mg/kg body weight). Mice were sacrificed on day 15 post challenge. MFG = micafungin,
ITC = itraconazole. Data are mean + SD (B,C). n = 4 (B) n = 5 (A,C). Log-rank (Mantel–Cox) test (A)
or two-tailed t-test (B,C) were used to identify significant differences. * p < 0.05; ns = not significant.

Different inbred mouse strains have differences in MHC haplotypes, immunophenotype features, and isoforms of metabolic enzymes which can contribute to varying rates of
drug metabolism [38,39]. Being so, we repeated our in vivo micafungin and itraconazole
susceptibility assay using an immunosuppressed C57BL/6 mouse model of disseminated
infection to compare C. auris susceptibility to that of A/J mice. C57BL/6 mice were immunosuppressed with cyclophosphamide prior to challenge with a sub-lethal dose of
C. auris AR-0389. Beginning 18 h post challenge, mice were administered micafungin or
itraconazole daily for 14 days and then sacrificed on day 15. As with our A/J mouse model,
we saw no protective effect using itraconazole, even with a higher dose (5.0 mg/kg/day)
(Figure 1C). Interestingly, with the minimum dose of micafungin, we observed a significant
reduction in fungal burdens in the kidney and brain (2.9 × 104 and 2.2 × 103 CFUs/g,
respectively) by day 15 as compared to DPBS mice kidney and brain burdens (5.5 × 106
and 3.4 × 104 CFUs/g, respectively). Comparing these results to our MIC data showed
that although C. auris AR-0389 is susceptible to both micafungin and itraconazole in vitro,
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only low-dose micafungin was effective at significantly reducing fungal burdens in immunosuppressed C57BL/6 mice. The data showed that C. auris is susceptible to minimum
doses of micafungin in vivo, but this could vary with mouse strain and cannot be predicted
solely using in vitro MIC data.
2.2. Candida Cell Surface Binding of Universal Candida-Specific Monoclonal Antibodies
Considering that antifungals have limited efficacy against multidrug-resistant C. auris,
we next investigated the protective efficacy of a panel of universal monoclonal antibodies
(mAbs) that target different Candida cell surface epitopes, which share high homology
among various Candida species (Table 2). First, we validated antibody binding to cell
surface epitopes by flow cytometric analysis using C. auris AR-0386 and AR-0389 and
C. albicans SC5314. We focused on three mAbs that were shown to be protective in our
preliminary studies: C3.1, which targets β-1,2-mannotriose (β-Man3 , IgG3), a mannose
sugar that is abundantly expressed and distributed on the outer cell wall of most Candida
species [40,41]; 6H1, which targets hyphal wall protein 1 (Hwp1, IgG2a), a cell wall
mannoprotein that is involved in adhesion, biofilm formation, and hyphal development in
several Candida species [42]; 9F2, which targets phosphoglycerate kinase 1 (Pgk1, IgG1),
a metabolic enzyme that is primarily involved in glycolysis and gluconeogenesis within
the cytoplasm [43,44].
Table 2. Universal Candida monoclonal antibodies and their cell surface targets.

1

Universal Antibody

Isotype

Cell Surface Target

C3.1 (anti-β-Man3 )
6H1 (anti-Hwp1)
9F2 (anti-Pgk1)
10E7 (anti-GPV-P3)

IgG3
IgG2b
IgG2a
IgG1

β-1,2-mannotriose
Hyphal wall protein 1
Phosphoglycerate kinase 1
Phosphoglycerate kinase 1 1

The 9F2 and 10E7 antibodies target two different epitopes on Pgk1.

Isolates were incubated with each primary mAb, washed, and then incubated with
goat anti-mouse secondary antibody conjugated to Alexa Fluor 488. Antibody binding
was then detected using flow cytometry (Figure 2A–C). C3.1 (anti-β-Man3 , IgG3) showed
56.6% binding to AR-0386, 98.4% binding to AR-0389, and 86.5% to C. albicans, while 6H1
(anti-Hwp1, IgG2b) showed binding of 38.1% to AR-0386, 2.6% to AR-0389, and 21.2% to
C. albicans. Finally, binding of 9F2 (anti-Pgk 1, IgG2a) was at 33.0% for AR-0386, 3.4% for
AR-0389, and 38.6% for C. albicans. Additionally, fluorescent microscopy imaging of cells
stained with each antibody (Figure 2D–F) depicted levels of fluorescence that corresponded
with our flow cytometry data. Since mannose sugars are abundantly expressed on the
outer cell wall [40,41], a high level of C3.1 binding in all isolates was expected. Pgk1 and
Hwp1, on the other hand, are not major components of the Candida cell wall and not as
abundantly expressed as β-Man3 , which was reflected in our mAb-binding data. It was,
however, surprising to see modest Hwp1 binding, since C. auris has not been demonstrated
to express Hwp1, and its genome has not been shown to contain an ortholog of the Hwp1
gene. This pointed to the possibility that our anti-Hwp1 mAb could be cross-reactive with
another C. auris cell wall protein, in which further investigation is required to identify the
target as well as confirm its sequence. It was also surprising to see such disparate levels
of 6H1 or 9F2 binding between the two C. auris isolates. The lower levels of 9F2 and 6H1
binding to AR-0389 could be an indication of epitope masking, which could explain the
higher level of virulence of this isolate, compared to AR-0386. Overall, the data showed
that the universal mAbs bind to C. auris in an isolate-specific manner.
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Figure 2. Cell surface binding of universal Candida-specific monoclonal antibodies: (A–C) flow cytometry scatter plots
depicting levels of cell surface binding of monoclonal antibodies as a measure of Alexa Fluor 488 expression in (A) C. auris
isolate AR-0386, (B) C. auris isolate AR-0389, and (C) C. albicans isolate SC5314; (D–F) confocal microscopy analysis (1000X)
showing antibody cell surface staining of (D) C. auris isolate AR-0386, (E) C. auris isolate AR-0389, and (F) C. albicans isolate
SC5314 using mAbs C3.1, 6H1, and 9F2. G11.2 = β-1,2-mannotriose (IgG1), C3.1 = β-1,2-mannotriose (IgG3), Hwp1 = hyphal
wall protein 1, Pgk1 = phosphoglycerate kinase 1. Bar = 25 µm.
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2.3. In Vivo Protective Efficacy of Universal Candida β-1,2-Mannotriose- and Peptide-Specific
Monoclonal Antibodies
We next evaluated if the prophylactic passive transfer of our universal mAbs would
protect mice against C. auris disseminated infection. We began with C3.1 (anti-β-Man3 ,
IgG3), a mAb that has previously been shown to be highly protective against C. albicans
disseminated bloodstream infections in mice [45]. Since the C. auris cell wall has a high
composition of β-1-2-mannans—reportedly even higher than in C. albicans [46], we hypothesized that mAb C3.1 would also protect against disseminated infection caused by
C. auris. To compare the efficacy of C3.1 to that of micafungin, A/J mice were treated
one time with C3.1 or DPBS or treated daily for 7 days with micafungin. 24 h after C3.1
treatment, mice were challenged with a sublethal dose of C. auris AR-0386. By day 35
post infection, there was a significant increase in survival of C3.1-treated mice (100% survival), compared to DPBS control mice (40% survival) (Figure 3A). Micafungin-treated
mice survival (60% survival) was not significantly extended, compared to the DPBS group.
When quantifying fungal burdens, C3.1-treated mice had a significant reduction in kidney
and brain burdens (1.2 × 104 and 5.0 × 101 CFUs/g, respectively), compared to control
mice (6.6 × 108 and 6.2 × 106 CFUs/g, respectively) (Figure 3B). Remarkably, all C3.1treated mice had undetectable brain burdens by day 35. While there was also a reduction
in heart burdens in C3.1-treated mice (8.2 × 102 CFUs/g), compared to DPBS control
(4.4 × 106 CFUs/g), this change was not statistically significant. Consistent with survival
data, there was no significant reduction in the kidney, brain, or heart burdens in micafungintreated mice (2.8 × 108 , 4.9 × 104 , and 4.4 × 106 CFUs/g, respectively), as compared to
DPBS mice. The data showed that mAb C3.1 treatment outperformed low-dose micafungin,
a gold-standard drug for the treatment of invasive C. auris infection in an A/J mouse model.

Figure 3. In vivo protective efficacy of universal Candida β-1,2-mannotriose-specific monoclonal antibody: (A) the 35-day
survival curve and (B) quantification of kidney, brain, and heart fungal burdens from 7-week-old female A/J mice treated
with mAb C3.1 or micafungin. Mice were treated with 200 µL DPBS, mAb C3.1 (0.24 mg/200 µL DPBS), or micafungin
(0.5 mg/kg body weight daily for 7 days) then challenged 18 h later with a sub-lethal dose of 4 × 107 CFUs of C. auris
AR-0386. β-Man3 = β-1,2-mannotriose. Data are mean + SD (B). n = 5. Log-rank (Mantel–Cox) test (A) or two-tailed t-test
(B) were used to identify significant differences. * p < 0.05; ns = not significant. ND = not detectable.
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We then evaluated the prophylactic efficacy of our peptide-specific mAbs. In addition to the mAbs 6H1 and 9F2, we also screened one additional universal mAb, 10E7,
which targets a different epitope on Pgk1 (GPV-P3, IgG1). A/J mice were treated with each
mAb, followed by a lethal dose challenge with C. auris AR-0386 18 h later. Survival was
observed for 40 days, and fungal burdens were quantified in the kidney, brain, and heart.
With this lethal challenge dose, all control mice died on day 5 post challenge (Figure 4A).
On the other hand, 9F2 and 10E7 mice had prolonged survival (50% and 25% survival,
respectively) by day 40, with 9F2 inducing significantly higher survival, compared to
control mice. Although not statistically significant, both mAb-treated groups had slightly
reduced fungal burdens in the kidneys, with 9F2 also inducing significantly lower heart
burdens (2.5 × 107 CFUs/g), compared to DPBS mice (2.1 × 108 CFUs/g) (Figure 4B).
This reduction in heart burdens is host significant, because A/J mice ultimately succumb to
cardiac failure, therefore making the heart the best indicator for evaluating disease progress
and protection [33,47]. There was no difference in brain burdens among mAb-treated and
control groups.

Figure 4. In vivo protective efficacy of universal Candida peptide-specific monoclonal antibodies: (A) the 40-day survival
curve and (B) quantification of kidney, brain, and heart fungal burdens from 7-week-old male A/J mice treated with two
Pgk1-specific mAbs; (A,B) mice were treated with 200 µL DPBS or antibody (0.285 mg/200 µL DPBS), then challenged
18 h later with a lethal dose of 1 × 108 CFUs of C. auris AR-0386; (C) quantification of kidney, brain, and heart fungal
burdens from 7-week-old female A/J mice treated with mAb 6H1 or micafungin. Mice were treated with 100 µL DPBS
or mAb (0.135 mg/100 µL DPBS), then challenged 18 h later with a sublethal dose of 4 × 107 CFUs of C. auris AR-0389.
GPV-P3 = phosphoglycerate kinase 1 (IgG1), Pgk1 = phosphoglycerate kinase 1 (IgG2a). Data are mean + SD (B,C).
n = 4. Log-rank (Mantel–Cox) test (A) or two-tailed t-test (B,C) were used to identify significant differences. * p < 0.05;
ns = not significant.
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In a separate experiment, we also tested the prophylactic protective efficacy of
6H1 (anti-Hwp1, IgG2b) in A/J mice using a sublethal challenge dose of C. auris AR0389. Mice were sacrificed on day 6, and fungal burdens were quantified as previously
(Figure 4C). Based on the data, 6H1-treated mice had lower fungal burdens in the kidney,
brain, and heart (3.8 × 107 , 6.7 × 105 , and 1.5 × 107 CFUs/g, respectively), compared to
DPBS mice kidney, brain, and heart burdens (2.9 × 108 , 1.8 × 106 , and 1.8 × 108 CFUs/g,
respectively). Of these, only the kidneys had a statistically significant reduction in fungal
burdens, while the reduction in heart burdens was nearly significant (p = 0.0798). Collectively, the data showed that passive transfer of universal Candida peptide-specific mAbs,
9F2 and 6H1 provided significantly extended survival (9F2) and significantly reduced
fungal burdens in the kidney (6H1) and heart (9F2), compared to control mice in an A/J
mouse model of C. auris disseminated infection.
2.4. In Vivo Protective Efficacy of Monoclonal Antibody Cocktails
Being that several of our antibodies were able to induce protection in mice when
administered individually, we further tested if combining two different mAbs would
induce enhanced or even synergistic protection in mice. Since our mAbs are specific
to different cell surface antigens, we hypothesized that using a cocktail of two mAbs
could result in a more effective “double hit” protection against C. auris. The selected twomAb cocktail consisted of 6H1, which performed best in the kidney (Figure 4C), and 9F2,
which performed best in the heart (Figure 4B). A/J mice were treated with 6H1, 9F2, or both,
followed by a sublethal dose challenge of AR-0386 24 h later. Survival was observed for
35 days. Mice that received the 6H1+9F2 cocktail had significantly higher survival (100%
survival) by day 35, compared to mice that received only 6H1 (20% survival) or 9F2 (0%
survival) (Figure 5A). Regarding fungal burdens (Figure 5B), mice that received the cocktail
had significantly lower burdens in the kidney (1.5 × 108 CFUs/g), compared to mice that
received only 9F2 (1.0 × 109 CFUs/g). Kidney burdens in the cocktail group were also lower
than in the 6H1 group (6.7 × 108 CFUs/g), although this was not statistically significant.
Similarly, fungal burdens in the brain were significantly lower in mice that received the
cocktail (5.8 × 103 CFUs/g), compared to mice that received only 9F2 (9.3 × 106 CFUs/g).
The cocktail group brain burdens were also lower than the 6H1 group (3.4 × 104 CFUs/g),
although this was not statistically significant. We also observed a consistent trend of lower
heart burdens for the mAb cocktail treated group (1.1 × 104 CFUs/g), compared to 6H1
mice (3.3 × 106 CFUs/g) or 9F2 (8.3 × 106 CFUs/g), although not statistically significant.
Overall, the data showed that protective mAbs, such as 6H1 and 9F2, can be combined into
cocktails to provide enhanced protection against C. auris disseminated infection compared
to treatment with either mAb individually.

Figure 5. Cont.
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Figure 5. In vivo protective efficacy of monoclonal antibody cocktails: (A) the 35-day survival curve and (B) quantification
of kidney, brain, and heart fungal burdens from 7-week-old female A/J mice treated with mAbs 6H1, 9F2, or a cocktail
of 6H1 + 9F2. Mice were treated with two 400-µL-doses of mAb 6H1 given 18 h apart, one 200-µL-dose of mAb 9F2, or a
combination of both mAbs consisting of one dose of 9F2 and two doses of 6H1 given 18 h apart. Then, 18 h after first dose
of mAb, mice were challenged with a sublethal dose of 4 × 107 CFUs of C. auris AR-0386. Hwp1 = hyphal wall protein 1,
Pgk1 = phosphoglycerate kinase 1. Data are mean + SD (B). n = 5. Log-rank (Mantel–Cox) test (A) or two-tailed t-test
(B) were used to identify significant differences. * p < 0.05; ** p < 0.01; ns = not significant.

3. Discussion
C. auris is the first fungal pathogen to cause a serious global public health threat [20].
In vitro and in vivo studies of drug efficacy against this MDR pathogen have shown that
most isolates are highly resistant to azoles and polyenes, which severely limits effective
drug treatments. As this pathogen easily spreads throughout hospital ICUs and assisted
living facilities, C. auris seriously threatens the lives of patients living with comorbidities.
In those who are most at risk, such as the immunocompromised, antifungal drugs are
often not effective and cause additional organ toxicity, which can further exacerbate the
conditions of these highly susceptible patients [19].
In this study, we demonstrated for the first time that passive transfer of Candida
peptide- and glycan-specific universal mAbs is an effective means of immunotherapy
for protecting against C. auris invasive infections in an established A/J mouse model.
During systemic infection, Candida spp. disseminates through the bloodstream and enters
target organs within hours of infection [48]. During early infection, Candida cells are rapidly
eliminated from circulation, and the pathogen is often undetectable in the blood [49].
Consequently, our study evaluated antibody efficacy by quantifying fungal burdens in the
kidney, brain, and heart, as well as overall survival. A key characteristic of our mAbs is that
they target epitopes that share high homology among various clinically significant Candida
species. This “universal” targeting allows for their potential application in preventing
candidemia caused by different Candida species and isolates regardless of isolate-specific
antifungal-resistance profiles.
The two C. auris isolates analyzed, AR-0386 (CAU-06) and AR-0389 (CAU-09), come from
different clades and have unique genetic variations resulting in isolate-specific morphologies,
rates of proliferation, virulence, and antifungal resistance [32]. These genetic differences
may also affect cell wall composition. The lower level of antibody binding observed with
isolate AR-0389 could be due to epitope masking by cell wall polysaccharides, which could
account for evasion of immune responses and higher levels of virulence observed with
isolate AR-0389, compared to AR-0386. This hypothesis is supported by evidence showing
that the unmasking of cell wall components, such as β-(1,3)-glucan, can lead to attenuated
C. albicans virulence in mouse models of systemic infection [50,51]. More work is required
to determine why the same mAb has different binding patterns to the cell surface epitopes
of C. auris isolates, and how this is related to isolate virulence, host–pathogen interaction,
and immune escape.
Of our mAb panel, C3.1 (anti-β-Man3 ) had the highest level of cell surface binding,
provided the best overall protection, and significantly outperformed micafungin as a
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treatment for invasive C. auris infection. β-mannose is a major glycan component of the
outer cell wall of many Candida spp., and it is abundantly expressed on the surface of
C. auris [46]. Our previous data with C. albicans has shown that C3.1-mediated protection
depends on its ability to rapidly and efficiently fix complement to the fungal surface,
which is associated with enhanced phagocytosis and killing of the fungus [40,45]. Being that
A/J mice are C3-competent, C3.1 likely protects against C. auris via the same mechanism.
Furthermore, it has been shown that immune complexes of IgG3 can bind to FcγRI receptors
on phagocytic cells [52]. Thus, C3.1 opsonization of C. auris may lead to additional FcγRI
binding, increased adherence and internalization, and enhanced phagocytosis; however,
quantitation of these values will be the subject of a later study.
In contrast to C3.1, 6H1 (anti-Hwp1) and 9F2 (anti-Pgk1) mAbs target epitopes that are
not abundantly expressed in the Candida cell wall, which was reflected in our flow cytometry data. Although Pgk1 is primarily a glycolytic enzyme localized in the cytoplasm, it is
also exposed on the Candida surface and has been identified as a cell-wall-associated moonlight protein that is immunoreactive during invasive fungal infections in humans [43,44,53].
Hwp1, on the other hand, is expressed on the cell surface during hyphal morphology [54];
however, some evidence does suggest that it may also be expressed during pseudohyphal
morphology [55], which has been induced in C. auris in vitro [56]. Interestingly, the C. auris
genome does not appear to contain an ortholog of the Hwp1 gene [54,56], which points
to the possibility of cross reaction of the anti-Hwp1 mAb with another cell wall protein.
Nonetheless, both mAbs were able to induce significant protection in our mouse model.
Our animal model also showed the enhanced efficacy of two-mAb cocktails as a prophylactic treatment against C. auris disseminated infection. A benefit of mAb cocktails is
that each antibody can individually induce a different effector mechanism, which can work
in concert to inhibit the growth and dissemination of the pathogen [57]. This is a strategy
that has been highly effective in treating other infectious diseases, such as HIV infection
using highly active antiretroviral therapy (HAART), which uses a cocktail of three or more
drugs that inhibit different steps of the virus’s replication cycle [58]. In the case of the
6H1+9F2 cocktail, the enhanced protection could be due to improved access of phagocytic
cells to C. auris yeast, leading to increased oxidative damage. Research conducted by other
groups has shown that Pgk1 confers protection to C. albicans against reactive oxygen species
(ROS) [59] and that immunization with recombinant Pgk1 protein leads to a significant
reduction in kidney burdens in mice infected with C. albicans or with C. glabrata [60]. Additionally, in an in vivo rat venous catheter model of infection, C. albicans Hwp1 mutants
were shown to display severe biofilm defects with few hyphae [61]. This may indicate
that 6H1 and 9F2 mAbs could function together to disrupt biofilm formation and increase
susceptibility to respiratory burst by phagocytic cells, although this mechanism would
need to be further investigated. Alternatively, the binding of one mAb could induce a
conformational change that results in the unmasking of the second mAb’s target epitope,
leading to functional cooperativity between mAbs targeting different epitopes. Further investigation may also show that these different mechanisms are not mutually exclusive and
may both contribute to the observed enhanced efficacy.
In recent years, several novel antifungal compounds have been developed that have
proven effective against MDR Candida species. One such compound, carvacrol, was shown
to have antifungal activity against clinical isolates of C. auris while also inducing synergistic antifungal activity when combined with fluconazole, amphotericin B, caspofungin,
and micafungin [62]. As with these compounds, mAbs have the potential to be combined
with antifungals to induce synergistic protection while also significantly reducing drug
MICs and associated toxicity. Future experiments will evaluate the enhanced protection of
combining our mAbs with conventional antifungals as well as the therapeutic efficacy of
these mAbs.
Finally, it is important to note that similar to most pathogenic Candida species, C. auris has the propensity to form biofilms within its host. It is well established that within
biofilms, Candida spp. exhibit higher resistance to antifungal drugs. This is largely due
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to the upregulation of efflux pumps [63] and the production of extracellular polymeric
substances (EPS), which can interfere with drug diffusion [64]. Although we observed
that micafungin was effective at reducing fungal burdens within our immunosuppressed
C57BL/6 model, this efficacy would likely be reduced against biofilm-derived C. auris cells.
In one mouse study of disseminated candidiasis using biofilm-derived C. glabrata cells, micafungin treatment was ineffective at reducing liver and kidney burdens [65]. MAbs could
be effective here as well. In one study, after incubating C. albicans and Candida dubliniensis
with antibodies targeting the surface antigen, complement receptor 3-related protein (CR3RP), both species had a reduction in surface adherence and in biofilm thickness in vitro [66].
Using a combination therapy, the binding of mAbs to the surface of the pathogen could
interfere with biofilm formation, leading to increased diffusion of antifungals.
In summary, the potential for mAb therapy against microbial pathogens is vast since
mAbs inherently have high specificity for their targets without selecting for resistance.
The application of protective mAbs against C. auris disseminated infection represents
a highly promising alternative to the often-ineffective use of antifungal drugs against
this MDR pathogen. Not only can effective mAbs protect against severe infection more
rapidly than antifungal drugs [67–69], but specific antibodies may also be synergistic with
conventional antimicrobials. The data presented here have significant implications for
both immunotherapy and vaccine development in the future, and the demonstration of
preclinical efficacy of the immunoprotective mAbs in this study will provide compelling
data that can be advanced into the clinical setting.
4. Materials and Methods
4.1. Candida Isolates and Culture Conditions
Two antifungal-resistant isolates of C. auris, AR-0386 (CAU-06) and AR-0389 (CAU-09),
were supplied by the United States Centers for Disease Control and Prevention (CDC,
Atlanta, GA, USA). C. albicans reference strain SC5314 was supplied by the American Type
Culture Collection (MYA-2876, ATCC, Manassas, VA, USA). For passive transfer of mAb
experiments, the inoculum was serially passaged daily for three days in 25 mL glucose yeast
peptide broth at 37 ◦ C and then washed three times in Dulbecco’s phosphate-buffered saline
(DPBS). Cell density was measured using a hemocytometer and adjusted to the desired
density in DPBS. For MIC assays, culture was plated onto Sabouraud Dextrose Broth (SDB)
agar plates and incubated at 35 ◦ C for 24 h. Five colonies were selected and suspended
in 1 mL of sterile deionized H2 O, and cell density was measured using a hemocytometer.
The density was then adjusted to desired concentration in RPMI 1640 + 0.165 M MOPS
medium (with L-glutamine and phenol red, without bicarbonate).
4.2. Mice
Male and female A/J mice were purchased from the Jackson Laboratory (JAX, Bar Harbor, ME, USA) and Envigo (Indianapolis, IN, USA). Male and female C57BL/6 mice were
purchased from the Jackson Laboratory (JAX, Bar Harbor, ME, USA). At the time of studies,
A/J mice were 7 weeks old, and C57BL/6 mice were 16–17 weeks old. Mice were maintained in the Louisiana State University Health Sciences Center’s AAALAC-accredited
animal facility (#000037, LSUHSC-NO, New Orleans, LA, USA), and all animal experiments were performed using a protocol approved by the Louisiana State University
Health Sciences Center’s Institutional Animal Care and Use Committee (#3559, 1/18/2019,
LSUHSC-NO IACUC, New Orleans, LA, USA).
4.3. Immunosuppression
16–17-week-old male and female C57BL/6 mice were immunosuppressed using cyclophosphamide monohydrate (#C0768, Sigma-Aldrich, St. Louis, MO, USA) three days
prior to challenge by intraperitoneal (i.p.) injection using a dose of 200 mg/kg of body
weight. Immunosuppression was maintained with additional i.p. injections of a 150 mg/kg
dose of cyclophosphamide every 7 days.
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4.4. Antifungals
Micafungin (≥97% HPLC) was purchased from Sigma-Aldrich (#SML2268, SigmaAldrich, St. Louis, MO, USA), and itraconazole (≥98% TLC) was purchased from SigmaAldrich (#I6657, Sigma-Aldrich, St. Louis, MO, USA). For MIC assay, micafungin and
itraconazole were dissolved in RPMI 1640 + 0.165 M MOPS medium (with L-glutamine and
phenol red, without bicarbonate) + 1% DMSO to the desired concentrations. For animal
experiments, micafungin was dissolved in DPBS to the desired concentration, and itraconazole was dissolved in sterile deionized H2 O + 10% DMSO to the desired concentration.
4.5. Antifungal Susceptibility
C. auris and C. albicans micafungin and itraconazole minimum inhibitory concentrations (MICs) were determined using the broth microdilution method (BMD) according to
the guidelines of the Clinical and Laboratory Standards Institute (CLSI) Reference Method
for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard (CLSI
M27-A3, 3rd Ed. 2008. Vol 28, No 14).
4.6. Antibodies
All monoclonal antibodies were isolated from hybridoma cells, purified, and sterile filtered in phosphate-buffered saline (PBS) by GenScript Biotech Corporation (GenScript, Piscataway, NJ, USA) and by Autoimmune Technologies (AiT, New Orleans, LA,
USA). Antibody concentrations were determined using a Pierce BCA Protein Assay Kit
(#23227, Thermo Scientific, Waltham, MA, USA), according to the manufacturer’s directions. A standard curve was constructed using bovine gamma globulin standard (BGG)
(#23212, Thermo Scientific, Waltham, MA, USA). Absorbance was read on a plate reader at
562 nm, and sample absorbances were compared to the BGG standard curve to determine
antibody concentration.
4.7. Antibody Titers
Titers of mAbs were determined via enzyme-linked immunosorbent assay (ELISA).
A 96-well polystyrene plate was coated with whole synthetic protein (Pgk1, Hwp1) (GenScript, Piscataway, NJ, USA) or mannan extract at 4 µg/mL in bicarbonate coating buffer
and incubated overnight at 4 ◦ C. The following day, the wells were blocked using 1% BSA
blocking buffer for 1 h at room temperature. Monoclonal antibodies were then added
in duplicate to respective wells using twofold serial dilutions from 1:500 to 1:256,000
and incubated for 2 h at room temperature. Horseradish peroxidase (HRP)-conjugated
goat anti-mouse polyvalent IgG, IgA, IgM secondary antibody (#A0412, Sigma-Aldrich,
St. Louis, MO, USA) was then added (1:3000) and incubated in the dark for 1 h at room
temperature. Tetramethyl benzidine (TMB) (#34022, Thermo Scientific, Waltham, MA, USA)
was then added to each well and incubated in the dark for 30 min at room temperature.
HCl was added to stop the reaction, and the optical density was measured at 450 nm using
a spectrophotometer. As a negative control, wells were incubated with secondary antibody
alone. Titers were given as the dilution whose OD reading was greater than two times that
of the negative control.
4.8. Antibody Cell Surface Staining
Overnight cultures of C. auris AR-0386, AR-0389, and C. albicans SC5314 were washed
three times with DPBS. Pellets were resuspended in 100 µL of C3.1 (anti-β-Man3 ),
9F2 (anti-Pgk1), or 6H1 (anti-Hwp1) antibodies in 1X PBS + 1% BSA and incubated for
1 h at room temperature. Cells were washed three additional times, and pellets were
resuspended in Alexa Fluor 488-conjugated goat anti-mouse IgG, IgM secondary antibody
(#A10680, Invitrogen, Carlsbad, CA, USA) (1:100) in 1X PBS + 1% BSA and incubated for
1 h at room temperature. Cells were washed three additional times and resuspended in
500 µL DPBS and acquired by flow cytometry at 488 nm (FACSDiva 8.0.3, FACSCanto II,
BD Biosciences, San Jose, CA, USA), As a positive control, an additional high-binding
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anti-β-Man3 mAb, G11.2 (IgG1), was used. As a negative control, cells were stained with
secondary antibody alone. Gating was set on the secondary antibody (Alexa Fluor 488 only)
control. A portion of the stained cells was spread on slides for fluorescent imaging.
4.9. In Vivo Model of Disseminated Infection
For this, 7-week-old A/J mice or 16–17-week-old immunosuppressed C57BL/6 mice
were treated via intraperitoneal (i.p.) injection with 200 µL of monoclonal antibody or
DPBS. Then, 18 h later, mice were challenged via intravenous (i.v.) injection in the tail vein
with C. auris AR-0386 at a sublethal dose of 4 × 107 CFUs in 100 µL DPBS or a lethal dose
of 1 × 108 CFUs in 100 µL DPBS or with C. auris AR-0389 at a sublethal dose of 4 × 107 in
100 µL DPBS, depending on the experiment. For experiments that measured antifungal
efficacy, mice received daily i.p. administration of micafungin or itraconazole starting 24 h
post challenge. All mice were monitored daily for death or the development of a moribund
state, at which point they were sacrificed via CO2 inhalation. All surviving mice were
sacrificed at the conclusion of each study.
4.10. Quantification of Fungal Burdens
Upon death, the kidney, brain, and heart were extracted from mice, and each organ
was homogenized in DPBS. The homogenate was then serial diluted and plated onto GYEP
agar plates containing chloramphenicol. The plates were incubated for 48 h at 37 ◦ C at
which time CFUs were quantified. The limit of detection was 50 CFUs/g for each organ.
4.11. Statistical Analysis
Plots and statistical comparisons were performed using Prism Software (Version 9,
GraphPad Software, San Diego, CA, USA). Survival data was evaluated by Kaplan–Meier
analysis, and statistical significance was calculated using a log-rank (Mantel–Cox) test.
For fungal burden data, results were expressed as mean ± SD, and statistical significance
was calculated using a two-tailed t-test to compare mAb-treated groups to the control group.
Each study contained five mice per group unless otherwise stated. Significant p values were
defined as follows: * p < 0.05; ** p < 0.01.
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